RHYTHM AI Ltd and Barts NHS Trust enter into an Exclusive Worldwide Licence Agreement for STAR Mapping™ Technology for Treatment of Atrial Fibrillation

Prof Richard Schilling

Oxford, UK- April 2019: RHYTHM AI Ltd (“RHYTHM AI” or “the company), a UK company focused on the treatment of Atrial Fibrillation (AF) today announces that it has entered into an exclusive worldwide licensing agreement with Barts NHS trust (London, UK) to develop and commercialise the STAR Mapping algorithm, an Artificial Intelligence driven cardiology mapping technology developed at Barts NHS Trust to improve outcomes of patients undergoing catheter ablation treatment for persistent AF.

RHYTHM AI Ltd is currently raising seed financing and anticipates publication of the STAR Mapping ‘first in man’ clinical study in spring 2019. The company plans to start recruitment into a multi-centre clinical study of STAR Mapping in mid-2020

Simon Hubbert, Executive Chairman of RHYTHM AI said: “We are delighted to sign this significant agreement which allows us to build on the excellent work of Professor Richard Schilling and his team at Barts NHS Trust. We look forward to the publication of the ‘First in man’ clinical study in the coming weeks and we are confident that we can demonstrate significantly improved results in the treatment of persistent AF in both single and multi centre studies.

Commenting on the agreement, Alwen Williams, Chief Executive Officer of Barts NHS Trust, said: We are very confident that his partnership with RHYTHM AI will lead to widespread clinical adoption of a new and revolutionary technology developed here at Barts Hospital. We look forward to working with the company and to other future collaborations that can prove the value of technology developed by the talented team at ‘Barts’.